Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.68 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12478623 | 0.96 | CNR1 (0.73) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL12685101 | 0.93 | CNR1 (0.69) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL14752451 | 0.92 | CNR1 (0.68) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL14739564 | 0.90 | CNR1 (0.66) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL14739704 | 0.90 | CNR1 (0.66) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL1604481 | 0.90 | CNR1 (0.66) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL14739566 | 0.90 | CNR1 (0.66) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL14746491 | 0.89 | CNR1 (0.64) | CNR1FAAHALDH1A1CNR2MEN1 | |
| SCHEMBL14739323 | 0.89 | CNR1 (0.64) | CNR1FAAHALDH1A1MEN1KMT2A | |
| SCHEMBL14740184 | 0.89 | CNR1 (0.64) | CNR1FAAHALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | FASN, FADS1, ELOVL5 | CNR1 1072/4885FAAH 29/4885ALDH1A1 810/4885 |
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | FASN, FADS1, ELOVL5 | CNR1 1072/4885FAAH 29/4885ALDH1A1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.